Orthopediatrics (KIDS) Stock
Specialized orthopedic implants and instruments maker for children. Here's the price, business snapshot, and what's worth knowing about Orthopediatrics in October 2026.
Orthopediatrics Corp (KIDS) designs, develops and sells paediatric orthopaedic implants, instruments and biologics tailored to children. The company focuses on smaller anatomies and specialised needs — plates, screws, spinal systems and growth modulation products — and supplies hospitals, surgeons and distributors across multiple markets. Revenue growth is typically driven by new product introductions, increasing surgeon adoption and selective acquisitions, while margins reflect manufacturing, R&D and distribution costs. With a market capitalisation around $449 million, KIDS is a small-cap medical devices company and can be more volatile than larger peers. Key factors to watch include product approvals, clinical outcomes, reimbursement trends, and the effectiveness of commercial roll-outs. Cash position and debt levels will influence its runway for innovation and expansion. This information is general and educational only, not personal advice; investors should assess suitability, perform their own research and be aware that values can fall as well as rise.
Orthopediatrics (KIDS) Stock Forecast
Analyst price target, next 12 months
$31.75
+43.3% vs today's $22.16
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Orthopediatrics have a consensus 12-month target of $31.75, above the current price of $22.16.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Orthopediatrics stock, expecting its price to rise significantly.
Financial Health
Orthopediatrics Corp is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Child-focused devices
Specialist products address paediatric needs and can command niche demand, though market uptake varies by surgeon familiarity and evidence.
Innovative pipeline
New product introductions and clinical data may drive adoption, but development and regulatory hurdles can delay commercial benefits.
Global expansion potential
International distribution offers growth opportunities, balanced by reimbursement differences and the costs of scaling operations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
